CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Tecfidera (dimethyl fumarate) — coverage criteria for relapsing multiple sclerosis

Covers FDA‑approved and compendial uses of Tecfidera for relapsing forms of multiple sclerosis when approval criteria are met; specifies prescriber specialty, 12‑month authorization and continuation criteria, and prohibits concomitant disease‑modifying MS therapies.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyTecfidera (dimethyl fumarate) coverage criteria for relapsing multiple sclerosis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization for up to 12 months and ensure prescription is by or in consultation with a neurologist; discontinue other disease‑modifying MS agents before approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsstandard authorization length

12 monthsclinically isolated syndrome auth

12 monthscontinuation auth if stable/improved

neurologistprescriber requirement

prohibitedconcomitant DMTs

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Tecfidera (dimethyl fumarate)

Initial and continuation therapy criteria

Covered when ALL of the following are met:

FDA or compendial indication: Medication is prescribed for an FDA‑approved or compendial indication (relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease)

All other indications are considered experimental/investigational and not medically necessary.

Prescriber specialty: Prescribed by or in consultation with a neurologist

Documentation should support the diagnosis and duration appropriate for authorization.

Authorization period: Initial and renewal authorizations may be granted for 12 months12 months

Renewal/continuation contingent on disease stability or improvement.

Concomitant therapy: Not used concomitantly with other disease‑modifying multiple sclerosis agents

Ensure other DMTs are discontinued prior to approval (Ampyra and Nuedexta are not disease‑modifying and may be used concomitantly).

Coverage is limited to FDA‑approved and compendial indications for Tecfidera (dimethyl fumarate). All other indications beyond the FDA‑approved uses listed are considered experimental/investigational and not medically necessary.

Uses of Tecfidera that are not for the FDA‑approved relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease) or other compendial indications are not medically necessary and will not be covered as standard therapy.

Provider Requirements and Authorization Rules

Prior Authorization

12-Month Prior Authorization

Authorization may be granted for up to 12 months for members diagnosed with relapsing forms of multiple sclerosis (including relapsing-remitting and secondary progressive disease who continue to experience relapse) and for members treated for clinically isolated syndrome. Continuation authorizations of 12 months may also be granted for members demonstrating disease stability or improvement while on the requested medication.

Authorization length: 12 months
Applies to: relapsing forms of MS (including relapsing-remitting and active secondary progressive) and clinically isolated syndrome
Continuation: 12-month renewals allowed for disease stability or improvement

Documentation Required

Prescriber and Diagnosis Documentation

This medication must be prescribed by or in consultation with a neurologist. Documentation supporting the diagnosis of a relapsing form of MS or clinically isolated syndrome and the treating neurologist's assessment must be provided with the prior authorization request.

Background

Tecfidera (dimethyl fumarate) is FDA‑approved for the treatment of relapsing forms of multiple sclerosis in adults, which includes clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease. The policy confines coverage to these FDA‑approved and compendial uses and requires that authorization criteria be met for approval.

Definitions

Relapsing forms of multiple sclerosis — definition

Clinically isolated syndromeIncluded as a relapsing form of multiple sclerosis per FDA indication.

Relapsing‑remitting multiple sclerosisIncluded as a relapsing form of multiple sclerosis per FDA indication.

Active secondary progressive diseaseIncluded as a relapsing form of multiple sclerosis per FDA indication.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyTecfidera (dimethyl fumarate) coverage criteria for relapsing multiple sclerosis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization for up to 12 months and ensure prescription is by or in consultation with a neurologist; discontinue other disease‑modifying MS agents before approval.

SourceLink

On This Page

Prescriber: neurologist or neurologist consultation required
Documentation: clinical diagnosis of relapsing MS or clinically isolated syndrome and rationale for therapy

Denial Risk

Non‑FDA / Non‑Compendial Uses

Use of this medication for indications that are not FDA‑approved or not supported by authoritative compendia is considered experimental/investigational and is not medically necessary. Requests for non‑FDA or non‑compendial uses will be denied.

Non‑FDA/Non‑compendial uses are considered experimental/investigational and not medically necessary
Examples: any indication other than treatment of relapsing forms of MS (including clinically isolated syndrome)

Denial Risk

Concomitant Therapy Restriction

Members must not use the requested medication concomitantly with other disease‑modifying multiple sclerosis agents. Approval may be denied if documentation shows concurrent use of another DMT. (Note: Ampyra and Nuedexta are not disease‑modifying agents and are exceptions.)

Concomitant DMT use prohibited: discontinue other disease‑modifying MS therapies prior to approval
Exceptions: Ampyra and Nuedexta are not considered disease‑modifying agents